Alkermes Brushes Off IP Pressures To Look to Potential Blockbuster Vivitrol
Recent intellectual property rulings have potentially been both positive and negative for specialty company Alkermes, which is still forecasting growing revenues driven by its marketed opioid addiction therapy and progress with its Phase III CNS products pipeline.
